Lung-targeted sLNP-delivered CMT-3 for sepsis-related ARDS
Official title: A Lung-Specific, Sulfonium Lipid Nanoparticle (sLNP) Formulation of Incyclinide for the Treatment of ALI/ARDS
Funded at Cmtx Biotech, INC. · NIH-11406986 · Data updated 2026-11-12
A new lung-targeted therapy using a sulfonium lipid nanoparticle to deliver CMT-3 therapy for adults with sepsis-associated ARDS.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $367,988 |
| NIH project number | 1R41HL184801-01A1 |
| Project ID | NIH-11406986 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with sepsis who are at risk of or have developed ARDS and receive hospital-based care.
✕Less likely to help
Patients without sepsis-associated ARDS or those not eligible for intravenous nanoparticle therapies may not benefit.
What this research studies
This project aims to treat acute respiratory distress syndrome caused by sepsis with a lung-targeted nanoparticle carrying a non-antibiotic tetracycline derivative. The approach uses a specialized delivery system designed to concentrate the drug in the lungs while reducing systemic exposure. If successful, the therapy could reduce lung damage, decrease progression to ARDS, and improve survival for adults with sepsis-related respiratory failure.
Why it matters
Potential benefit: If successful, patients with sepsis-induced ARDS could experience better lung protection and survival.
How similar studies have gone: Previous work supports safety of CMT-3 in humans and the nanoparticle approach shows promise in targeted lung delivery, though this exact therapy is novel.
Where this research is happening
-
Cmtx Biotech, INC.
Kings Park, United States Active
Researchers
- Principal investigator: Li, Yamin — Cmtx Biotech, INC.
- Study coordinator: Li, Yamin
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.